Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
N-(Phosphonacetyl)-L-aspartate (PALA) suppressed the growth of Ehrlich ascites tumour cells in vivo in a dose-dependent manner. Simultaneously as the growth rate decreased, the cellular uptake of glucose and the density of a class of glucose-reversible binding sites for cytochalasin B on the cell surface were also found to be reduced. There is a highly significant correlation between the magnitude of changes in the number of cytochalasin B binding sites and the magnitude of changes in glucose uptake. The physiological significance of these observations are discussed.
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001665:Binding Sites; D001692:Biological Transport / Q000187:drug effects; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003571:Cytochalasin B / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000378:metabolism; D007700:Kinetics; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D009943:Organophosphorus Compounds; D001224:Aspartic Acid; D003571:Cytochalasin B; C013195:sparfosic acid; D005947:Glucose; D010746:Phosphonoacetic Acid